Bibliografía:

1. Bates SM, Ginsberg JS: Treatment of deep-vein thrombosis. N. Engl. J. Med. 2004; 351: 268-277.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593.
3. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
4. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
5. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med 2001;1:7-26.
6. Parodi R, Greca A. Anticoagulación. En: Battagliotti C, Greca A. Terapéutica Clínica. Editorial Corpus. Rosario, Argentina. 2005.
7. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
8. Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet 1999; 354: 1229-33.
9. Lowe GDO. Blood rheology and venous thrombosis. Clin Hemorheol 1984; 4: 571-88.
10. Pearson TC. Rheology of the absolute polycythaemias. Baillieres Clin Haematol 1987; 1: 637-64.
11. Fuchs S, Heyse T, Rudofsky G, et al. Continuous passive motion in the prevention of deep-vein thrombosis. A randomised comparison in trauma patients. J. Bone Joint Surg 2005; 87 B: 1117-1122.
12. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update software.
13. Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999; 81: 879-86.
14. Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226: 306-13.
15. Nicolaides AN, Arcelus J, Belcaro G, Bergqvist D, Borris LC, Buller HR, et al Prevention of venous thromboembolism. European Consensus Statement, 1-5 November 1991, developed at Oakley Court Hotel, Windsor, UK. Int Angiol 1992; 11: 151-9.
16. Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109: 82-5.
17. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg 1992; 74: 50-2.
18. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P, et al. Prevention of deep-vein thrombosis after knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999; 81: 654-9.
19. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am 1998; 80: 1158-66.
20. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg 1995; 77: 6-10.
21. Murray DW, Carr AJ, Bulstrode CJ. Pharmacological thromboprophylaxis and total hip replacement. J Bone Joint Surg 1995; 77: 3-5.
22. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
23. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MK, Bafi AS, Petro KR, Corso PJ. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J. 2005; 26(6): 576-83.
24. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg. 2005 Sep; 80(3): 922-7.
25. Fareed J, Haas S, Sasahar A. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue. Semin Thromb Hemost 1999; 25 Suppl 3: 145-7.
26. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomised trials in general, orthopedic and urologic surgery. N Engl J Med 1988; 318: 1162-73.
27. Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet 1977; 1: 567-9.
28. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta analyses. Br J Surg 1997: 84: 750-9.
29. Koch A, Ziegler S, Breitschwerdt H, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis; meta-analysis based on original patient data. Thromb Res 2001; 102: 295-309.
30. Green D. Prophylaxis of thromboembolism in spinal cord-injured patients. Chest 1994;102:Suppl A:649S-651S.
31. Merli GJ, Crabbe S, Doyle L, Ditunno JF, Herbision GJ. Mechanical plus pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury. Paraplegia 1992;30:558-562.
32. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707.
33. Weitz JL. Low molecular-weight heparins. N Engl J Med 1997; 337: 688-699.
34. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9.
35. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-4.
36. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 Suppl 1: 64S-94S.
37. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta analyses. Br J Surg 1997: 84: 750-9.
38. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
39. Berqvist D, Breddin K, Ten Cate JW, Davidson JF, Haas S, Leyvraz PF et al. Thromboprophylaxis in hip fracture surgery: A pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 1999; 29: 310-7.
40. Eriksson BI, Ekman S, Lindbratt B, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with the use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractioned heparin in patients having total hip replacement. J Bone Joint Surg Am 1997; 79: 326-33.
41. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
42. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35.
43. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002; 359: 1710-1.
44. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;
    271: 1780-5.
45. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001; 119 Suppl 1: 132-75.
46. Barbier P, Jonville AP, Autret E, Coureau C. Fetal risks with dextrans during delivery. Drug Saf 1992; 7: 71-3.
47. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1829.
48. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review. Ann Intern Med 1992;116:754-761.
49. Hirsh J, Prins MH, Samama M. Approach to the thrombophilic patient for hemostasis and thrombosis: basic principles and clinical practice. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: J.B. Lippincott, 1994:1543-61.
50. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
51. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998; 339: 93-104.
52. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 1994;71:15-18.
53. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335: 108-114.
54. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995;108:Suppl:305S-311S.
55. Diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Evidence Report/Technology Assessment No. 68. AHRQ Publication No. 03-E012. Rockville, Md.: Agency for Healthcare Research and Quality, January 2003. Accessed online March 25, 2005, at: http://www.ahrq.gov/clinic/epcsums/dvtsum.htm.
56. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest 2005;127:416]. Chest 2004; 126(3 suppl): S401-28.